VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 410 filers reported holding VALEANT PHARMACEUTICALS INTL in Q4 2013. The put-call ratio across all filers is 0.62 and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2015 | $8,132,000 | -52.4% | 80,000 | -16.5% | 0.29% | -57.4% |
| Q3 2015 | $17,101,000 | -55.0% | 95,865 | -44.0% | 0.67% | -46.4% |
| Q2 2015 | $38,023,000 | +31.1% | 171,160 | +17.2% | 1.25% | +25.2% |
| Q1 2015 | $29,005,000 | +18.3% | 146,029 | -14.8% | 1.00% | +6.2% |
| Q4 2014 | $24,518,000 | -24.7% | 171,331 | -30.9% | 0.94% | -2.3% |
| Q3 2014 | $32,552,000 | +47.0% | 248,110 | +41.3% | 0.96% | +30.5% |
| Q2 2014 | $22,150,000 | +12.0% | 175,623 | +17.1% | 0.74% | +43.6% |
| Q1 2014 | $19,775,000 | -52.8% | 150,000 | -57.9% | 0.51% | -59.7% |
| Q4 2013 | $41,875,000 | +418.3% | 356,687 | +360.6% | 1.28% | +323.6% |
| Q3 2013 | $8,079,000 | +6.0% | 77,433 | -12.5% | 0.30% | -7.1% |
| Q2 2013 | $7,619,000 | – | 88,505 | – | 0.32% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Chou Associates Management | 1,648,992 | $38,323,000 | 14.52% |
| Paulson & Co. | 20,839,035 | $484,299,000 | 9.89% |
| MILLER VALUE PARTNERS, LLC | 4,999,064 | $116,178,000 | 4.34% |
| GoldenTree Asset Management | 1,140,205 | $26,498,000 | 4.21% |
| Pomelo Capital LLC | 1,760,000 | $40,902,000 | 4.00% |
| Bruce & Co., Inc. | 860,000 | $19,986,000 | 3.98% |
| ValueAct Holdings | 18,033,149 | $419,090,000 | 3.79% |
| Stanley Capital Management, LLC | 318,400 | $7,400,000 | 3.25% |
| Kazazian Asset Management, LLC | 134,784 | $3,132,000 | 2.87% |
| Phoenix Investment Adviser LLC | 58,400 | $1,357,000 | 2.48% |